Aptinyx Inc.
Formerly Enarex, Inc., Eranix, Inc.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2017 | $70 M | No. 2 | $50 to $250 million | equity | SEC | |
| May 2016 | $25 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Aptinyx Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2017).
SEC Form D · Dec 2017
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Dec 2017
That is all the official record says: Aptinyx Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
17 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Adams Street Partners LLC | Fund or asset manager | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Andrew Kidd | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2018) | SEC Form 3 |
| Ashish Khanna | Person | not stated | not stated | Held Series A-1, A-2 and B preferred stock (Form 3, 2018) | SEC Form 3 |
| David Houck | Person | not stated | not stated | Held Series A-1, A-2 and B preferred stock (Form 3, 2018) | SEC Form 3 |
| FHM Life Sciences VIII, L.L.C. | Other | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| FHM Life Sciences VIII, L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Frazier Life Sciences VIII, L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Joseph R. Moskal | Person | not stated | not stated | Held Series A-1, A-2 and B preferred stock (Form 3, 2018) | SEC Form 3 |
| Longitude Capital Partners II, LLC | Fund or asset manager | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Longitude Venture Partners II, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| New Leaf Biopharma Opportunities I, L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| New Leaf BPO Associates I, L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| New Leaf Venture Associates III, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| New Leaf Venture Management III, L.L.C. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| New Leaf Ventures III, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Norbert G. Riedel | Person | not stated | not stated | Held Series A-1, A-2 and B preferred stock, director (Form 3, 2018) | SEC Form 3 |
| Torsten M. Madsen | Person | not stated | not stated | Held Series A-1, A-2 and B preferred stock (Form 3, 2018) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 63 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Andrew D. Kidd | Chief Commercial Officer | Dec 2017 |
| Ashish M. Khanna | Chief Business Officer | Dec 2017 |
| Joseph R. Moskal | Chief Scientific Officer | Dec 2017 |
| Norbert G. Riedel | President & Chief Executive Officer | Dec 2017 |
| Torsten M. Madsen | Chief Medical Officer | Dec 2017 |
| Ashish G. Khanna | Secretary & Chief Business Officer | May 2016 |
| Adam M. Koppel | Director | Dec 2017 |
| James P. Topper | Director | Dec 2017 |
| Liam P. Ratcliffe | Director | Dec 2017 |
| Norbert G. Riedel | President & Chief Executive Officer | Dec 2017 |
| Patrick H. Enright | Director | Dec 2017 |
| Terry P. Gould | Director | Dec 2017 |
| Wilbur H. Gantz III | Director | Dec 2017 |
| James N. Topper | Director | May 2016 |
| Patrick G. Enright | Director | May 2016 |